Ocean Biomedical Inc (NASDAQ: OCEA) is a clinical-stage biopharmaceutical company that in-licenses early-stage drug candidates from academic and research institutions and advances them through preclinical and clinical development. The company generates no product revenue, funding operations through debt issuances, warrant exercises, and equity raises. Ocean Biomedical's pipeline spans oncology, fibrosis, and malaria, sourced primarily through partnerships with Brown University and Rhode Island Hospital. Preclinical development of its oncology, fibrosis, and malaria programs was funded through grants to its licensors totaling $105.6 million prior to in-licensing, per the 10-K filed April 8, 2025. The company employs contract research organizations and contract manufacturing organizations for drug development. Ocean Biomedical reported zero cash on its consolidated balance sheet as of December 31, 2024, operates in stockholders' deficit, and carries short-term loans, SPA warrants, and fixed maturity obligations among its liabilities. Material weaknesses in internal controls over financial reporting were identified as of the same date.

Revenue model

No product revenue as of FY2024. The company finances operations through short-term loans, convertible notes, and equity and warrant issuances. One loan facility with Second Street Capital carried a 15% per annum interest rate. No licensing, royalty, or commercial product revenue is disclosed in the filing.

Products and services

Pipeline of in-licensed drug candidates across oncology, fibrosis, and malaria indications. The malaria program incorporates the Whole Proteome Differential Screening (WPDS) antigen discovery platform. All candidates were in preclinical or early clinical stages as of the 10-K filed April 8, 2025.

Customers and end markets

No commercial customers as of FY2024. Target end markets are patients with oncological, fibrotic, and infectious diseases, specifically malaria. Potential future customers would include hospital systems, government payers such as Medicaid and Medicare, and entities participating in 340B drug pricing programs.

Value-chain role

Biotech drug developer positioned between academic research institutions (upstream licensors) and eventual clinical or commercial partners (downstream). Sources candidates from universities and medical centers, then advances them using CROs and CMOs rather than internal research or manufacturing infrastructure.

Geographic exposure

Headquartered in the United States. Regulatory disclosures reference FDA, EU member state requirements, and UK MHRA post-Brexit frameworks, indicating an awareness of international regulatory environments, though no commercial operations outside the US are disclosed in the filing.

Source: SEC 10-K, filed 2025-04-08

Industry: Pharmaceutical Preparations